Medicines for acute forms of leukemia will be launched in St. Petersburg.
The innovative Russian drug Sibcordia (vamotinib) has been registered with the Ministry of Health. The development will be used for the treatment of chronic myeloid leukemia.
The pharmaceutical substance is produced by Bratskkhimsintez, and the finished medicine, packaging and quality control will be carried out at the Pharmasynthesis-Nord site in St. Petersburg. Sibcordia's export deliveries are scheduled to begin in 2028.
As it became known 78.ru , the drug was registered under the conditional registration procedure. This mechanism is used for innovative medicines intended for the treatment of orphan and severe diseases. In addition, it provides for further collection of efficacy and safety data after registration.
Earlier it was reported that Russia has adopted, but has not implemented, a law on the import of newly registered medicines in the country. It was assumed that at first they could be imported in original packages, where the information was presented in a foreign language. However, a decree that should determine the specifics of the importation has not appeared.
Переведено сервисом «Яндекс Переводчик»